Revolutionizing Patient Care: ProPharma and PBL Launch Innovative Cell & Gene Therapy Manufacturing Device
RALEIGH, N.C., May 2, 2024 /PRNewswire-PRWeb/ -- ProPharma, the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, today announced that in partnership with PBL, it developed an enclosed, fully automated cell factory device, the Cell Factory Box (CF Box). This innovative, new device enables decentralized manufacturing of all types of Cell & Gene Therapies (CAGT) in Class D (ISO8) or c.n.c. surrounding areas.
- This innovative, new device enables decentralized manufacturing of all types of Cell & Gene Therapies (CAGT) in Class D (ISO8) or c.n.c.
- Our collaboration with PBL positions us to serve those in the CAGT segment fully," said Eleonora Casucci, Vice President of Quality & Compliance EU at ProPharma.
- The CF Box uses already-approved AI technology and extensive automation to dramatically reduce manual operation and the need for high-class clean rooms.
- "We are honored to work with ProPharma on such a monumental effort," said Filippo Begarani, Research and Innovation Manager of PBL.